Tech Company Financing Transactions
IGM Biosciences Funding Round
IGM Biosciences closed a $102 million Series C venture capital round on 7/9/2019. Investors included Haldor Topsoe, Janus Henderson Investors and Redmile Group.
Transaction Overview
Company Name
Announced On
7/9/2019
Transaction Type
Venture Equity
Amount
$102,000,000
Round
Series C
Proceeds Purpose
Proceeds from this financing will be used to advance the Company's IgM platform technology and its proprietary oncology pipeline, including its lead program, a CD20 x CD3 bispecific antibody, which is expected to enter the clinic later this year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
325 East Middlefield Rd.
Mountain View, CA 94043
USA
Mountain View, CA 94043
USA
Phone
Website
Email Address
Overview
We are a biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer patients. IgM antibodies have inherent properties that we believe may enable them to improve upon the efficacy and safety of IgG antibodies in multiple therapeutic applications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Fred Schwarzer
Chief Financial Officer
Misbah Tahir
Chief Medical Officer
Daniel Chen
Chief Scientific Officer
Bruce Keyt
Vice President
Stephen Carroll
Vice President
Wayne Godfrey
Vice President
Angus Sinclair
VP - Human Resources
Suzette Tauber
VP - Manufacturing
Marvin Peterson
Browse more venture capital transactions:
Prev: 7/9/2019: Kaleidoscope Labs venture capital transaction
Next: 7/10/2019: Cesium venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to record funding rounds that are announced publicly. VC transactions on this site are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs